In line with recent mouse model studies [51] where chronic oral administration of myristic acid improved hyperglycemia by decreasing insulin-responsive glucose levels and reducing body weight, myristic acid in our enrichment pathway is a fatty acid that appears to be associated with obesity but not with MetS. The gene discussed is INS; the disease is metabolic syndrome.